PDCD1 and neoplasm: The Food and Drug Administration (FDA) and the European Union have approved several immune checkpoint inhibitors and monoclonal antibodies for clinical tumor treatment, such as CTLA4 monoclonal antibody ipilimumab, PD1 monoclonal antibody nivolumab, etc. [34].